Skip to main content
SpringerLink
Log in

Hematology

Setting the standard for newly diagnosed multiple myeloma

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

The treatment of multiple myeloma has evolved rapidly with the use of the immunomodulatory agents thalidomide and lenalidomide as well as the proteasome inhibitor bortezomib. Cavo and colleagues recently reported results of a landmark phase III study comparing thalidomide–dexamethasone with bortezomib–thalidomide–dexamethasone in newly diagnosed multiple myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Harousseau, J. L. Ten years of improvement in the management of multiple myeloma: 2000–2010. Clin. Lymphoma Myeloma Leuk. 1 0, 424–442 (2010).

    Article  Google Scholar 

  2. Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N. Engl. J. Med. 335, 91–97 (1996).

    Article  CAS  Google Scholar 

  3. Attal, M. et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349, 2495–2502 (2003).

    Article  CAS  Google Scholar 

  4. Rajkumar, S. V. et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26, 2171–2177 (2008).

    Article  CAS  Google Scholar 

  5. Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29–37 (2010).

    Article  CAS  Google Scholar 

  6. Harousseau, J. L. et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial. J. Clin. Oncol. 28, 4621–4629 (2010).

    Article  CAS  Google Scholar 

  7. Mitsiades, N. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377–2380 (2003).

    Article  CAS  Google Scholar 

  8. Cavo, M. et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376, 2075–2085 (2010).

    Article  CAS  Google Scholar 

  9. Chanan-Khan, A. A. & Giralt, S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J. Clin. Oncol. 28, 2612–2624 (2010).

    Article  CAS  Google Scholar 

  10. Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679–686 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana Farber Cancer Institute, 44 Binney Street, Boston, 02115, MA, USA

    Jacob Laubach, Paul G. Richardson & Kenneth Anderson

Authors
  1. Jacob Laubach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul G. Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacob Laubach.

Ethics declarations

Competing interests

P. G. Richardson is on advisory boards of the following companies: Bristol-Myers Squibb, Celgene, Johnson & Johnson, Millenium and Novartis. K. Anderson is a consultant at the following companies: Bristol-Myers Squibb, Celgene, Onyx, Merck, Millenium and Novartis. J. Laubach declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laubach, J., Richardson, P. & Anderson, K. Setting the standard for newly diagnosed multiple myeloma. Nat Rev Clin Oncol 8, 255–256 (2011). https://doi.org/10.1038/nrclinonc.2011.43

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.43

  • Springer Nature Limited

Search

Navigation